Charles River Laboratories International, Inc. (CRL)
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
Charles River Laboratories International Inc CRL reported second-quarter 2024 revenue of $1.03 billion on Wednesday, a decrease of 3.2% year over year, beating the consensus of $1.024 billion.
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.69 per share a year ago.
Charles River cuts 2024 forecast as funding crunch among biotech clients persists
Charles River Laboratories trimmed its annual forecast on Thursday, as it no longer expects demand for its drug discovery and development services to improve in the second half of the year, sending its shares down 15% in premarket trading.
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Inks CDMO Deal With Gates Institutes
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE:CRL) breached their fiduciary duties to CRL and its shareholders. What can I do?
